All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62157124%3A16810%2F20%3A43878454" target="_blank" >RIV/62157124:16810/20:43878454 - isvavai.cz</a>

  • Result on the web

    <a href="https://www.frontiersin.org/articles/10.3389/fonc.2020.01047/full" target="_blank" >https://www.frontiersin.org/articles/10.3389/fonc.2020.01047/full</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.3389/fonc.2020.01047" target="_blank" >10.3389/fonc.2020.01047</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus

  • Original language description

    Somatostatin analogs mantain their major role in the treatment of patients with advanced neuroendocrine tumors (NETs) and have multiple modulatory effects on the immune system. Here, we evaluated the effects of lanreotide treatment on expression of Th1, Th2 cytokine patterns in serum of patients with NETs and in bronchial and pancreatic NET cell lines. Our results showed that lanreotide treatment promoted a Th1 cytotoxic immune-phenotype in patients with NETs originated by intestinal sites. Similar results were obtained alsoin vitrowhere lanreotide induced expression of Th1 cytokines only in pancreatic and not in bronchial-derived NET cell lines. It seems, therefore, that cytokinomics can represent a useful tool for the identification of tumor biomarkers for the early diagnosis and evaluation of the response to therapy in NET patients. To avoid the drug-resistance induced by everolimus (mTOR inhibitor), we made the pancreatic NET cell line resistant to this drug. After treatment with lanreotide we found that the drug reduced its viability compared to that of sensitive cells. These data may have direct implications in design of future translation combination trial on NET patients.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    40301 - Veterinary science

Result continuities

  • Project

    <a href="/en/project/NV16-28637A" target="_blank" >NV16-28637A: Bones, tendons and ligaments extent defects healing with using of new biomaterials</a><br>

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2020

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Frontiers in Oncology

  • ISSN

    2234-943X

  • e-ISSN

  • Volume of the periodical

    10

  • Issue of the periodical within the volume

    JUL

  • Country of publishing house

    CH - SWITZERLAND

  • Number of pages

    13

  • Pages from-to

  • UT code for WoS article

    000555540200001

  • EID of the result in the Scopus database